Projet: TALETE (Transcan-3 ERA-NET, Europe)

À propos

Targeting acute myeloid leukemia immunosuppressive microenvironment by combined IDO1 inhibition and PD-1 blockade

Type: European.
Duration: 2023–2027 (36 months).
Partners & funding amounts: University Hospital Bologna (Curti lab, AUOBO), DKFZ (Opitz lab); amount for team: 220 k€; consortium total ≈ 1.3 M€.
Responsibilities: Co-PI; work package leader.
Theme & content of work: Integrates single-cell immunophenotyping, immunometabolism (SCENITH) and epigenetics to detect early AML microenvironment resistance mechanisms (e.g., IDO1–tryptophan axis) linked to durable dysfunction and therapy response.
Scope & impact: Diagnostic/selection platform and actionable biomarkers for personalized AML immunotherapy.

Home